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Summary
IgG4-related disease (IgG4-RD) is an immune-me-
diated condition, characterized by the formation of
fibroinflammatory tumefactive lesions that can
cause progressive tissue damage and subsequent
organ failure. Although initially described as a dis-
ease of unknown etiology confined to the pan-
creas, IgG4-RD has been realized over time as an
important entity that has underlies numerous
pathologic conditions such as autoimmune pan-
creatitis, Riedel thyroiditis, Mikulicz syndrome, in-
flammatory pseudotumors and many others.
IgG4-RD can affect almost any organ. However,
the most commonly affected are the pancreas, he-
patobiliary system, exocrine glands (salivary,
lacri mal), retroperitoneum, kidneys and intratho-
racic structures. Within the thorax, involvement of
the lung parenchyma, airways, mediastinum, and
pleura have been reported. The pulmonary in-
volvement, therefore, is very diverse and can pres-
ent as pulmonary nodule(s) or mass(es), alveolar
or interstitial infiltrates, airflow obstruction, lym-
phadenopathy, mediastinal fibrosis, and pleural
thickening and/or effusion. It is therefore impor-
tant to recognize the diverse manifestations of
this condition, as it can involve multiple organs
and have various forms of expression within the
same organ. As a consequence, IgG4-RD has pre-
sented a fascinating diagnostic challenge for
many different specialties. In this review, we focus
on the diagnosis and management of the intratho-
racic involvement in this multisystem disease. 
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Introduction 
The IgG4-related disease (IgG4-RD) is a multisystem
disorder characterized by the formation of fibroinflam-
matory tumefactive lesions that can lead to progres-
sive fibrosis, tissue destruction and subsequent organ
failure (1, 2). It can present with involvement in one or
multiple organs. Single-organ involvement is present in
about 40% of patients at the time of presentation (3, 4).
For those with multiorgan involvement, the lesions may
present synchronously or metachronously. The two
main features of IgG4-RD are tissue infiltration with
IgG4-positive plasma cells and the elevation of serum
IgG4 (not present in all patients) (1, 5).
IgG4-RD is a recently recognized disease process. In
1995, Yoshida et al. (6) described a form of chronic
autoimmune pancreatitis that was associated with hy-
perglobulinemia and postulated an autoimmune
mechanism as the cause of the pancreatic injury. In
2001, Hamano et al. (7), identified a relationship be-
tween high serum IgG4 levels and sclerosing pancre-
atitis. However, it was not until 2003 that Kamisawa et
al. (8), designated for the first time the term “IgG4-re-
lated autoimmune disease”. They recognized that pa-
tients who had autoimmune
pancreatitis could have ex-
tensive injury in other tis-
sues as well. These Au-
thors comprise the pio-
neers in uncovering the ex-
istence of a previously un-
recognized disease entity
caused by underlying au-
toimmune mechanisms (8). 
Subsequently, several studies
documented the association between the characteris-
tic lesion of dense lymphoplasmacytic infiltrates con-
taining IgG4-positive plasma cells in various organs
including salivary gland (IgG4-related sialadenitis) (9,
10), lacrimal gland (IgG4-related dacryoadenitis) (9,
11), the bile duct (IgG4-related sclerosing cholangitis)
(9, 12), liver (IgG4-related hepatopathy) (9), kidneys
(IgG4-related kidney disease) (9, 11), aorta (IgG4-re-
lated aortitis/periaortitis) (9, 13), retroperitoneum
(IgG4-related retroperitoneal fibrosis) (9, 10), lymph
nodes (IgG4-related lymphadenopathy) (9, 10, 14)
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and lungs (IgG4-related lung disease) (9, 11, 15) with
high serum IgG4 levels. In 2012, a consensus of ex-
perts with broad representation from different special-
ties officially recommended using the term “IgG4-re-
lated disease” and unified an appropriate nomencla-
ture for this spectrum of diseases (previously also re-
ferred to as “hyper-IgG4 disease” and “IgG4-related
sclerosing disease”) (16). Herein, we summarize clin-
ically relevant aspects of intrathoracic IgG4-RD, fo-
cusing on the point of view of the pulmonologists. This
review describes the diverse intrathoracic manifesta-
tions, associated findings, diagnostic process, and
treatment strategies. We also discuss the clinical
course and prognosis. 
General and epidemiologic aspects of IgG4-RD
IgG4-RD can be a diagnostic challenge as it mimics
many other processes including neoplasms, infec-
tions, and autoimmune diseases. Overrepresentation
in the literature of the most challenging and severe
cases is a potential bias and has to be taken into con-
sideration when evaluating epidemiologic aspects of
this disease. IgG4-RD seems to be more common in
men (Ratio of 1 to 0.7) (9, 17-19) with the possible ex-
ception of those with mainly head and neck involve-
ment in whom the male to female ratio is nearly equal
(9). It usually affects middle-aged to older individuals,
with a median age of 60 to 65 years (2, 17) with only
few sporadic cases under 18 years of age (2, 3). 
The IgG4-RD is a condition described in all races al-
though initially described predominantly in Asians.
Successively, cases have been reported in subjects
with differing ethnic back-
grounds and various re-
gions of the world. The pre-
dominance of Asians in the
literature describing cases
of IgG4-RD was likely due
to the fact that Japanese
physicians were the first to
recognize these cases, and
therefore had a broader ex-
perience in the diagnosis of this disease. 
Symptomatology associated with IgG4-RD depends
on the organ involved and includes abdominal pain
(40%), sicca symptoms (15%), respiratory symptoms
(13%), pruritus (13%), and diarrhea (6%) (4, 20). Pa-
tients may also present with constitutional complains
such as weight loss, fatigue, and low-grade fevers (3,
4, 20). Additionally, some subjects may be asympto-
matic at the time of diagnosis and present with only
abnormalities on laboratory testing or imaging studies
(2, 17). 
IgG4-RD may have an unpredictable clinical course
whether one or multiple organs are involved at the
time of diagnosis. However, once the disease is rec-
ognized, it usually responds well to treatment. A mi-
nority of cases can progress to a life-threatening situ-
ation such as rupture of inflammatory aneurysms,
coronary syndromes, and hypertrophic pachymeningi-
tis or progressive organ damage despite immunosup-
pressive therapy (21-24). 
Pathogenesis of IgG4-related disease 
The pathogenesis of this disease remains an unfin-
ished puzzle though several theories have been pos-
tulated. Herein, we review some of the hypotheses
that have been proposed. 
The genetic background is likely to influence how the
individual responds to environmental exposures or
lifestyle factors and it likely influences the evolution of
autoimmune and other chronic inflammatory condi-
tions. In the particular case of IgG4-RD, various ge-
netic risk factors have been reported to play a role in
the susceptibility to this disease, among which the
HLA (human leukocyte antigen) serotypes DRB1*
0405 and DQB1*0401 have been associated with in-
creased predisposition in the Japanese population
(25). Additionally, single-nucleotide polymorphisms in
the tumor necrosis factor α, cytotoxic T-lymphocyte-
associated antigen, and Fc receptor-like 3 have been
implicated in susceptibility IgG4-RD to but study re-
sults have been inconsistent (17, 25-27). 
IgG4 is the least abundant of the IgG family. It repre-
sents only 3 to 6% of the total IgGs; and presents in
variable concentrations in healthy subjects, usually
ranging from 0.01 to 1.4 mg/ml (1, 28). Among IgG4-
RD patients, 70 to 90% of the patients have an elevat-
ed serum IgG4 level (>140 mg/dL). However, it should
be noted that the serum IgG4 level is elevated in up to
5% of the normal population (28-30). The exact role of
IgG4 in the pathogenesis of this disease is not well-
understood and it is questionable whether IgG4 itself
is the true driver of the inflammatory process. 
IgG4 is a special form of IgG with respect to the struc-
tural, functional, and immunologic regulation. One of
its unique characteristics is that IgG4 forms a dimer
incorporating half of its own molecule and half from a
different IgG4; this half-antibody exchange reaction is
referred to as fragment antigen-binding (Fab)-arm ex-
change (2). This phenomenon occurs because, unlike
other subclasses of IgG, the heavy chain has no cova-
lent bonds and the disulfide bridges are incompetent
(due to a single amino acid difference in the hinge re-
gion) (31, 32) allowing the IgG4 to randomly dissoci-
ate and regroup with other IgG4 molecules resulting in
varying antigen-binding specificities. This half-anti-
body exchange can bind two different antigens but
rarely associate with each other to form large immune
complexes (33, 34). This is one of the reasons why
IgG4 has traditionally been
viewed as non-inflammatory
component and whose pri-
mary function is to mitigate
rather than accelerate or in-
cite a chronic immune re-
sponse. 
In addition to the individual
genetic predisposition, sev-
eral theories have been
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postulated regarding infectious processes and autoim-
munity as possible triggers for IgG4-RD. One is the
observation that physiologic IgG4 responses can be
induced by prolonged or repeated antigen exposures.
Therefore, it is possible that the abundance of circulat-
ing IgG4 could be a reaction to an unidentified primary
inflammatory stimulus.  Second is that the formation of
IgG4 antibodies directed against some microbial anti-
gens could potentially act as autoantibodies to self-
antigens through molecular mimicry in those who are
genetically predisposed (1, 2). For instance, it has
been shown that some patients with IgG4-related au-
toimmune pancreatitis have antibodies against the
plasminogen-binding protein of H. pylori (35). Third,
certain antibodies are directed to respond to autoanti-
gens, some of which are expressed in exocrine glands
such as lactoferrin, trypsinogens, pancreatic secreto-
ry trypsin inhibitor, and carbonic anhydrases. Reaction
to these antigens may explain some of the IgG4-RD
systemic manifestations (1, 36). However, these au-
toantibodies are not known to be a part of the IgG4
subclass nor specific for IgG4-RD (1, 37, 38).
Another important theory that may shedd some light
into the pathogenesis of IgG4-RD comes from the ob-
servation that some of these patients respond well to
B-lymphocyte depletion therapies (2, 39, 40). It is
therefore possible that activated IgG4+ B-lymphocytes
and plasmablasts may drive the pathogenesis of
IgG4-RD either directly through autoantibody assem-
bly or indirectly through the activation of pathogenic
CD4+ T cells (2).  
Overview of intrathoracic involvement in IgG4-RD
Even though IgG4-RD was beginning to be recog-
nized in the late 1990s, it was not until 2004 that pul-
monary involvement in this disease was documented.
Taniguchi et al. reported a patient with autoimmune
pancreatitis and bilateral interstitial infiltrates in the
lower lung fields (41). Transbronchial lung biopsy
showed marked thickening of the alveolar septae with
infiltration of IgG4+ plasma cells. Duvic et al. (42) re-
ported a patient with pancreatic and retroperitoneal fi-
brosis, elevated serum IgG4 level, and nodular pul-
monary opacities. Surgical lung biopsy demonstrated
histopathologic features of organizing pneumonia.
Both patients were treated with corticosteroids with a
good response. Subsequent studies have reported a
wide variety of intrathoracic findings. Interestingly, the
most frequently affected intrathoracic component is
the lymph nodes (17, 43-45). But involvement of other
compartments including the lung parenchyma, air-
ways, vasculature, and pleura and have also been re-
ported. In 2005, Zen et al. reported inflammatory
pseudotumour of the lung with IgG4+ plasma cell infil-
tration and suggested that clinicopathological similari-
ties exist between inflammatory pseudotumours and
autoimmune pancreatitis (46). It seems, therefore,
that the IgG4-related lung disease can manifest vary-
ing forms of involvement resembling many other dis-
ease processess in the lung. 
L. Arvelo Castro et al.
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Table 1 - Patterns of intrathoracic involvement in IgG4-RD.
Parenchymal
Nodules or masses 
Interstitial lung disease
Airways
Tracheobronchial stenosis 
Extrinsic compression of large airways
Pleural
Pleural mass 
Pleuritis/fibrosis 
Pleural effusion
Mediastinal
Lymphadenopathy
Fibrosing mediastinitis
Pulmonary vascular disease
Pulmonary arterial hypertension 
There are two features of IgG4-related lung disease
that continue to be incompletely understood and need
further investigation. First, it is unclear how often pul-
monary involvement occurs in patients with IgG4-RD. A
cross-sectional study of 114 patients with the IgG4-RD,
found that 16 (14%) patients had lung or pleural lesions
(9). A retrospective multicenter study of 235 IgG4-RD
patients reported only 13 (5.5%) patients to have lung
involvement (47). Secondly, it is unknown whether the
behavior of IgG4-RD in the lung may be modified by fac-
tors such a smoking or concomitant lung disease such
as COPD or asthma.
Clinical features of intrathoracic IgG4-RD 
Patients with intrathoracic IgG4-RD are often asymp-
tomatic at presentation with incidental abnormalities
detected by imaging studies performed for unrelated
indications. Among patients with abnormal chest im-
aging studies related to IgG4-RD approximately 38%
have respiratory symptoms, usually consisting of
cough and exertional dyspnea (3, 15, 48). Less com-
mon symptoms include hemoptysis, chest pain, low-
grade fever and weight loss (15, 48). Intrathoracic in-
volvement in IgG4-RD can be classified according to
anatomic compartments as shown in Table 1. 
Parenchymal lung disease
Parenchymal lung involvement in IgG4-RD are mainly
of two types: rounded opacities [nodules (≤3 cm in di-
ameter) or masses (>3 cm in diameter)] and interstitial
lung disease (ILD) (11, 15, 17, 43, 48-53). Rounded
opacities may be solid or ground-glass density and
can exhibit variable dimensions, from sub-centimeter
(<1 cm) to pulmonary masses (>5 cm) (11, 15, 17, 43,
46, 48). Multiple or single rounded opacities can be
observed on chest radiography or CT with no particu-
lar anatomical predilection (Figure 1) (15, 17, 43, 48,
49). Recently, a case of cavitating lung disease in
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IgG4-RD was reported (54). Rounded opacities usual-
ly raise suspicion of malignancy, particularly when as-
sociated with irregular margins (17, 43, 49). Thus, pa-
tients with these types of focal lung lesions not  un-
commonly undergo surgical resection (17). 
The radiological features of interstitial involvement of
IgG4-related lung disease are heterogeneous. Previ-
ous reports described bilateral interstitial pattern con-
sisting in ground-glass opacities in the lower lung
fields associated with honeycombing (17, 41).  Subse-
quent reports have described widely varying radiolog-
ical patterns including reticular opacities (irregular
lines), patchy ground-glass opacities, alveolar consol-
idation, and thickening of the bronchovascular bun-
dles and interlobular septa (11, 15, 17, 42, 43, 48, 49).
Patients with these types of pulmonary involvement
usually manifest a restrictive pattern along with a re-
duced diffusing capacity on pulmonary function testing
(17).
Airway disease
Several cases of airway involvement in IgG4-RD have
been reported. Ito et al. described a 63-year-old
woman previously diagnosed with autoimmune pan-
creatitis that presented with a persistent cough and
was noted to have irregular tracheobronchial stenosis
on bronchoscopic inspection. Pulmonary function test-
ing showed an obstructive pattern and chest CT re-
vealed intrathoracic lymphadenopathy along with
thickening of the bronchovascular bundle (17, 55). In-
oue et al. (56) reported a 56-year-old woman who pre-
sented with exertional dyspnea. Chest radiography re-
vealed stenosis of main bronchi bilaterally and spirom-
etry demonstrates severe obstructive impairment. CT
scanning in this patient revealed a diffuse mass in the
mediastinum (“sclerosing mediastinitis”) that involved
the main bronchi bilaterally. A
thoracotomy was per-
formed with partial excision
of the tissue mass which
exhibited infiltration with
many IgG4+ plasma cells
(17, 56). 
Several patients diagnosed
with IgG4-RD have been
reported to present with
asthma-like symptoms, peripheral blood eosinophilia
and elevated serum IgE level (57, 58). However, it re-
mains to be determined whether the findings repre-
sent mere coexistence of two diseases or pathogeni-
cally related entities. Zen et al. (15) reported a retro-
spective study of 21 patients among whom 9 (43%)
had features of atopy and 6 (29%) had a diagnosis of
asthma. In addition, Della Torre et al. (57) observed el-
evated serum IgE level in 35% of patients and periph-
eral blood eosinophilia in 27%. These Authors con-
cluded that elevated serum IgE level peripheral
eosinophilia are related to the immune response in
IgG4-RD rather than to an underlying atopic condition
(57). 
Pleural disease
IgG4-related pleural disease can present alone, ac-
company parenchymal lung lesions, or with extrapul-
monary involvement (17, 59, 60). Pleural manifesta-
tions in IgG4-RD mainly include three features: pleu-
ral mass, pleuritis with fibrosis, or pleural effusion
(Figure 2). Zen et al. (15) reported pleural lesions in
24% of their 21 patients. The pleural lesions were
nodular and involved the visceral and parietal pleura
as well as the chest wall. All 5 patients had both
parenchymal and pleural involvement (15). There
have also been reports of patients presenting with
symptomatic pleural effusions, sometimes bilateral
and massive (49, 61, 62). A pleural fluid analysis
demonstrated an exudative character with cellular
constituents comprising mainly of lymphocytes and
plasma cells (61). 
Mediastinal disease
Most common intrathoracic manifestation is probably
lymphadenopathy in the mediastinum and/or hilar re-
gions and has been described in 40% to 100% of pa-
tients with IgG4-RD (10, 11, 15, 43, 44, 63). Matsui et
al. (63) reported a retrospective review of 18 patients
diagnosed with intrathoracic IgG4-RD among whom
hilar lymphadenopathy was noted in all patients as de-
tected by CT scanning, gallium-citrate or 18-fluo-
rodeoxyglucose positron emission tomography. 
Fibrosing mediastinitis is an uncommon manifestation
of  IgG4-RD but may respond to corticosteroid thera-
py (17, 56, 64). This is notable since fibrosing medias-
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Figure 1 - Chest CT of a 55-year-old man with IgG4-relat-
ed lung disease consisting of multiple solid irregularly mar-
gined nodules bilaterally. Transbronchial biopsy demon-
strated interstitial and perivascular lymphoplasmacytic infil-
trate with 30 IgG4+ plasma cells per high power field and
90% IgG4+/IgG+ plasma cell ratio. PET scan demonstrated
FDG uptake in multiple organs including the lungs, medi-
astinal lymph nodes, salivary glands, lacrimal glands, and
the pancreas. 
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tinitis is generally considered a condition refractory to
corticosteroid therapy (17). 
Pulmonary vascular disease
Involvement of the pulmonary vasculature is rare in
IgG4-RD, but recently, cases of pulmonary arterial hy-
pertension associated with IgG4-RD have been re-
ported (65, 66). In one such report of a 22-year-old
woman, chest CT revealed multiple small pulmonary
nodules along with thickening of bronchovascular
bundles and interlobular septae (65). She was docu-
mented to have pulmonary hypertension by echocar-
diography and right heart
catheterization. The pul-
monary hypertension and
CT abnormalities improved
rapidly after beginning corti-
costeroid therapy. The Au-
thors hypothesized the
mechanism of pulmonary hy-
pertension to be obliterative arteritis affecting the pul-
monary arteries caused by IgG4-RD. 
Laboratory findings 
Basic laboratory tests such as complete blood cell
counts and biochemical profiles often provide nonspe-
cific indications of organ impairment (67). Mild-to-mod-
erate peripheral eosinophilia is found in 34% of patients
with IgG4-RD (4). Serum IgG4 level is elevated (>140
mg/dL) in the majority of patients with intrathoracic
IgG4-RD (29, 67-70). However, an elevated serum IgG4
level is a relatively insensitive and nonspecific biomark-
er in the diagnosis of IgG4-RD (29, 30, 67, 71). 
Kerbs von den Lungen-6 (KL-6) is a circulating high-
molecular weight glycoprotein (MUC1 mucin) ex-
pressed by type II pneumocytes in the lung (17). This
biomarker has been reported to be elevated in pa-
tients with various ILDs including idiopathic pulmonary
fibrosis (17, 72, 73). Hirano et al. (50) reported pul-
monary involvement in 4 of 30 patients with autoim-
mune pancreatitis and the serum levels of KL-6 was
elevated in all 4 patients. Additionally, the serum KL-6
level has been noted to decrease with glucocorticoid
therapy in patients with IgG4-related lung disease
(74). Nonetheless, the utility of serum KL-6 level in pa-
tients with intrathoracic IgG4-RD remains to be clari-
fied. 
The usefulness of other immunological markers such
as rheumatoid factor, anti-nuclear antibody and in-
flammatory biomarkers such as erythrocyte sedimen-
tation rate and C-reactive protein, is limited, consider-
ing that these nonspecific biomarkers tend to rise in
many inflammatory disorders (49, 75). Recent studies
suggest that circulating plasmablast levels are elevat-
ed in patients with IgG4-RD and may correlate with
disease activity (76, 77). Additional studies are need-
ed in assessing the role of plasmablast levels as a
biomarker in this disease.
The IgG4 level in the bronchoalveolar lavage fluid
(BAL) seems to correlate with the serum IgG4 level
and patients with IgG4-related lung disease have
higher levels of IgG4 in the BAL compared to patients
with sarcoidosis (17, 43). As expected from histopa -
thological findings, BAL cellularity consists predomi-
nantly of lymphocytes and the CD4+/CD8+ lymphocyte
ratio tends to be normal (17, 43, 55, 63). However, the
BAL data concerning to IgG4-related lung disease are
sparse and the role of BAL in the evaluation of pa-
tients with IgG4-related lung disease remains to be
clarified. 
Histopathology
Histopathological findings remain the diagnostic key-
stone of IgG4-RD (4, 75). These findings are better
depicted on surgical lung biopsy but can also be rec-
ognized on bronchoscopic
biopsy (17). Transthoracic
needle biopsy may be use-
ful in excluding malignan-
cies in patients with focal
lesions, but may not pro-
vide sufficient tissue to con-
firm a diagnosis of IgG4-RD
(4, 17, 75). 
Many of the histopathologi-
cal features of pulmonary
involvement in IgG4-RD are
similar to those appreciated in those with extrapul-
monary lesions but there are also some differences.
The key morphological points shared with extrapul-
monary IgG4-related lesions include lymphoplasma-
L. Arvelo Castro et al.
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Figure 2 - Chest CT of a 70-year-old man with IgG4-relat-
ed autoimmune pancreatitis and pleural fibrosis. Chest CT
scan demonstrated multiple regions of pleural thickening
within the right hemithorax including focal nodular thicken-
ing anteriorly and more diffuse thickening posteriorly. Tho-
racoscopic pleural biopsy demonstrated sclerosing pleuritis
with dense lymphoplasmacytic infiltrates containing >30
IgG4+ cells per high power field. 
The mechanism of
pulmonary hyperten-
sion is pulmonary
obliterative arteritis
caused by IgG4-RD.
The key morphologi-
cal points shared
with extrapulmonary
IgG4-related lesions
include lymphopla-
smacytic inflamma-
tion, increased num-
bers of IgG4⁺ plasma
cells, fibrosis and
phlebitis.
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cytic inflammation, increased numbers of IgG4+ plas-
ma cells, fibrosis and phlebitis (9, 17, 48, 78, 79).
Eosinophilic infiltration into the interlobular septae,
peribronchioles and pleura can be prominent but gran-
ulomas are seldom present and tend to be small and
vague (9, 17, 63, 79).  Plasma cells comprise the main
cell type of the inflammatory infiltrates, followed by
lymphocytes and histiocytes (9, 17). 
In the lung, the collagenized fibrosis and active fibrob-
lastic proliferation are more predominant than in au-
toimmune pancreatitis, whereas distinct storiform fi-
brosis is often not seen (4, 17, 79). Obliterative arteri-
tis and/or phlebitis  has been described in both pul-
monary veins and arteries in contrast to the findings in
the involved pancreas which show obliterative
phlebitis with sparing of the arteries (17, 78, 79).  
The appropriate cut-off values for the number of IgG4+
plasma cells per high-power field differ depending on
the organ involved (60, 75, 80). Several studies report
the IgG4+/IgG+ plasma cell ratio in tissue over 40% to
have aproximatly 85% specificity for diagnosing IgG4-
RD (60, 80). Nevertheless, numerous disorders, in-
cluding multicentric Castleman’s disease, rheumatoid
synovitis, carcinoma-associated inflammatory re-
sponse, and other nonspecific inflammatory respons-
es can exhibit high IgG4+ plasma cell counts and
IgG4+/IgG+ ratios. 
Diagnosis of IgG4-RLD
In patients who already have an established diagnosis
of IgG4-RD, concern regarding pulmonary involve-
ment may arise when respiratory symptoms occur or
intrathoracic abnormalities are noted on imaging. In
2015 an expert consensus panel agreed that the re-
sults of clinical evaluation, laboratory analysis, and
imaging studies are generally insufficient to distin-
guish the lesions of IgG4-RD from other diseases.
Therefore, diagnostic confirmation by histopathologic
analysis of the intrathoracic lesion is recommended
for the exclusion of malignancies and other processes
that may present in a similar manner (81). Ryu et al.
(17) proposed several criteria to diagnose IgG4-relat-
ed lung disease (RLD) including the presence of a
histopathologic lesion characterized by a fibroinflam-
matory process (in the absence of an infection), with
or without nodular formation, and the presence of
plasma cells that comprise >50% of inflammatory infil-
trates with endothelialitis in the pulmonary arteries
and/or veins (17, 78). Inter-
lobular septal and pleural
involvement is commonly
present (17). IgG4+ plasma
cells are increased with
>50 IgG4+ plasma cells
seen per high power field
with IgG4+/IgG+ plasma cell
ratio of >40% (75). The di-
agnosis of IgG4-RD can be
reached in the presence of
these histopathological find-
ings along with compatible clinical and radiologic fea-
tures that do not suggest an alternative disorder. 
Differential diagnosis
The differential diagnosis for IgG4-RLD may include a
large number of disorders due to its protean manifes-
tations. Thus the disease entities that need to be con-
sidered in this regard depend on the abnormal feature
being evaluated as outlined in Table 2. 
Treatment
The primary goal for treatment of IgG4-RD is the pre-
vention of irreversible fibrosis and organ damage
which can occur within weeks or months (81). In-
trathoracic IgG4-RD, similar to extrapulmonary le-
sions, responds well to corticosteroid therapy  (1, 15,
17, 41, 42, 44, 48, 60, 63, 78, 81, 82). The optimal
dose of corticosteroid therapy in the treatment of
IgG4-RD is not exactly known, but most experts rec-
ommend oral prednisone at an initial dosage of 30 to
40 mg/day (81, 83). The dosage may be adjusted
based on body weight. If the disease appears to be
particularly aggressive in its
behavior, 1 mg/kg per day
can be used. 
The initial corticosteroid
dosage should be main-
tained for 2 to 4 weeks (81).
Favorable response is typi-
cally seen by 2 weeks on
treatment, after which it can
be tapered gradually over
the following weeks to
months with close monitoring for possible recurrence
Lung and airway disorders in immunoglobulin G4-related disease
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Table 2 - Differential diagnosis for IgG4-RLD.
Diseases with similar pulmonary presentations
Neoplastic disorders, including lymphoma (nodular
opacities) 
Infections, including lung abscess (nodular opacities ±
cavitation) 
Interstitial pneumonias (interstitial infiltrates) 
Asthma (airway disease) 
Diseases with multi-system involvement 
Connective tissue diseases 
Vasculitis, especially granulomatosis with polyangiitis
(Wegener) 
Sarcoidosis 
Diseases with pulmonary inflammation and increased
IgG4+ plasma cells 
Granulomatosis with polyangiitis (Wegener) 
Eosinophilic granulomatous with polyangiitis (Churg-
Strauss) 
Multicentric Castleman’s disease 
Rosai-Dorfman disease 
There is lack of con-
sensus among ex-
perts and the eviden-
ce regarding the use
of immunosuppres-
sive therapy other
than corticosteroids
in the treatment of
IgG4-RD is limited.
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(17). The practice at many centers is to discontinue
corticosteroid use 3 to 6 months after the start of treat-
ment while others advocate low-dose maintenance
therapy for a longer period to reduce the risk of re-
lapse (12, 81, 84-86). Optimal duration of mainte-
nance therapy has not been determined. 
Not all intrathoracic manifestations of IgG4-RD require
immediate treatment. For example, “watchful waiting”
may be appropriate, in patients with asymptomatic in-
trathoracic lymphadenopathy (63, 81). 
Spontaneous remissions of IgG-RD, at least tempo-
rary, without treatment, have been reported (81, 87,
88). However, spontaneous improvement in intratho-
racic IgG4-related lung disease has not been docu-
mented. While corticosteroid therapy is used com-
monly in patients with IgG4-related lung disease, it is
not necessary in the management of patients who un-
dergo complete surgical resection of a solitary pul-
monary nodule or mass that represents the sole man-
ifestation IgG4-RD (9, 15, 17). 
There is lack of consensus among experts and the
limited evidence regarding the use of immunosuppres-
sive therapy other than corticosteroids in the treat-
ment of IgG4-RD (81). The addition of steroid-sparing
agents seems appropriate when the corticosteroid
dosage cannot be decreased due to persistently ac-
tive disease, particularly when adverse effects of cor-
ticosteroid therapy have occurred (81). In certain situ-
ations such as in patients known to be at increased
risk of adverse effects from corticosteroids or situa-
tions requiring prolonged treatment, combining a
steroid-sparing agent with corticosteroid therapy at
the start of treatment can be considered (81). Steroid-
sparing agents that have been used in the treatment
of IgG4-RD include azathioprine, mycophenolate
mofetil, 6-mercaptopurine, methotrexate, tacrolimus,
and cyclophosphamide (17, 81). The efficacy of these
agents has not been assessed in prospective clinical
trials. 
The B cell depletion therapy with rituximab has shown
promising results in retrospective studies, even in pa-
tients in whom treatment with other steroid-sparing
agents has been unsuccessful (43, 89-92). Addition of
rituximab therapy for patients on corticosteroids can
facilitate reduction of corticosteroid dosage (40, 81).
Recently, Carruthers et al. (40) reported the results of
an open-label pilot trial of rituximab therapy in 30 pa-
tients with IgG4-RD. Favorable disease response that
was maintained at 6 months was seen in nearly all pa-
tients and only 8 participants required prednisone
treatment at any point in the trial (40). Optimal use of
B-cell depletion therapy in IgG4-RD remains to be de-
termined. 
Prognosis
The outcome in IgG45-RD appears to depend on sev-
eral parameters including patient-specific factors
(age, sex) and disease-specific factors such as dis-
ease duration and extent of disease (e.g., single-or-
gan vs multi-organ involvement) (93). Relapse of dis-
ease is relatively common during the steroid tapering
process and may necessitate reescalation of the cor-
ticosteroid dose or and/or addition of a steroid-sparing
agent (81, 93, 94). Thus, some experts have advocat-
ed the use of prolonged maintenance therapy, typical-
ly low-dose corticosteroids, to prevent relapses (1, 81,
95). In addition, the response to corticosteroid therapy
seems to vary according to the affected organs and
the stage of disease (degree of fibrosis). Some pa-
tients with IgG4-RD may not experience complete res-
olution of their disease and exhibit evidence of resid-
ual disease. For example, Zen et al. (15) reported
residual radiologic abnormalities after treatment in
14% of patients with IgG4-related pleuro-pulmonary
disease. 
Conclusions
IgG4-related intrathoracic disease comprises varying
patterns of involvement and can  affect nearly all com-
ponents in the thorax including the lung parenchyma,
airways, pleura, pulmonary vasculature and the medi-
astinum. The diagnosis of IgG4-RD should be consid-
ered in patients presenting with a persistent or recur-
rent inflammatory process which appears to be char-
acterized by lymphoplasmacytic infiltration of the tis-
sue with fibrosis. IgG4-RD may account for a portion
of various idiopathic fibroinflammatory disorders en-
countered in the thorax including  inflammatory pseu -
dotumors, idiopathic interstitial pneumonias, asthma-
like airway disease, nodular pleural lesions, and fi-
brosing mediastinitis. 
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